18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: In comparison with vascularity, Ki-67, p53, and histologic grade

European Radiology

Volumn 17, Issue 2, 2007, Pages 409-417

  Cho, Song Mee ^a   Park, Yong Gyu ^a   Lee, Joon Mo ^a   Byun, Jae Young ^a   Lee, Jae Mun ^a   Lee, Kyo Young ^a   Park, Gyeong Sin ^a   Kim, Hyeon Sook ^b   Lee, Bae Young ^b   Lee, Kang Hoon ^b   Song, Kyung Sup ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

18F FDG PET; Cancer biology; CT; MRI; Ovary cancer

Indexed keywords

CONTRAST MEDIUM; DIAZEPAM; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; GADOLINIUM; KI 67 ANTIGEN; PROTEIN P53; SCOPOLAMINE BUTYL BROMIDE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER SIZE; CELL DENSITY; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; CYSTADENOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MITOSIS RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SECOND LOOK SURGERY; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; TUMOR VOLUME; UNDIFFERENTIATED CARCINOMA;

ADULT; AGED; ANALYSIS OF VARIANCE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846458245     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-006-0326-y     Document Type: Article

References (37)

1. Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebreachts CP (1997) Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 204:513-520
2. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman (2002) Peritoneal metastases: Detection with spiral CT in patients with ovarian cancer. Radiology 223:495-499
3. Karlan BY, Hawkins R, Hoh C et al (1993) Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 51:175-181
4. Zimny M, Siggelkow W, Schroder W et al (2001) 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83:310-315
5. Torizuka T, Nobezawa S, Kanno T et al (2002) Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Eur J Nucl Med Mol Imaging 29:797-803
6. Cho SM, Ha HK, Byun JY et al (2002) Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol 179:391-395
7. Nakamoto Y, Saga T, Ishimori T et al (2001) Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 176:1449-1454
8. Bristow RE, del Carmen MG, Pannu HK et al (2003) Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 90:519-528
9. Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, Haller U, Steinert HC (2000) Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 10:761-767
10. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893-901
11. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2006) Detection of residual tumor after radiofrequency ablation on liver metastasis with dual-modality PET/CT: Initial results. Eur Radiol 16:80-87
12. Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Gorges R, Muller SP, Bockisch A, Debatin JF, Brandau W (2004) Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14:2092-2098
13. Kallinowski F, Schlenger KH, Runkel S et al (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49:3759-3764
14. Hatanaka M (1974) Transport of sugars in tumor cell membranes. Biochim Biophys Acta 355:77-104
15. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B (1998) FDG accumulation and tumor biology. Nucl Med Biol 25:317-322
16. Kurokawa T, Yoshida Y, Kawahara K et al (2004) Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109:926-932
17. Zhao S, Kuge Y, Mochizuki T et al (2005) Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 46:675-682
18. Munkarah AR, Coleman RL (2004) Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95:273-280
19. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
20. Obermair A, Wasicky R, Kaider A et al (1999) Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett 138:175-182
21. DiSaia PJ, Bloss JD (2003) Treatment of ovarian cancer: New strategies. Gynecol Oncol 90:S24-S32
22. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K (2002) Lung tumors evaluated with FDG-PET and dynamic CT: The relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 26:185-190
23. Veronesi G, Landoni C, Pelosi G et al (2002) Fluoro-deoxy-glucose uptake and angiogenesis are independent biological features in lung metastases. Br J Cancer 86:1391-1395
24. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186
25. Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 46:945-952
26. Choi SJ, Kim JS, Kim JH et al (2005) [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 32:653-659
27. Muzi M, Vesselle H, Grierson JR et al (2005) Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: Validation studies in patients with lung cancer. J Nucl Med 46:274-282
28. Buck AK, Hetzel M, Schirrmeister H et al (2005) Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 32:525-533
29. Cobben DC, Elsinga PH, Suurmeijer AJ et al (2004) Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-L-thymidine. Clin Cancer Res 10:1685-1690
30. Francis DL, Freeman A, Visvikis D et al (2003) In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52:1602-1606
31. Mayr D, Diebold J (2000) Grading of ovarian carcinomas. Int J Gynecol Pathol 19:348-353
32. Sengupta PS, McGown AT, Bajaj V et al (2000) p53 and related proteins in epithelial ovarian cancer. Eur J Cancer 36:2317-2328
33. Hernandez E, Rosenshein NB, Bhagavan BS, Parmley TH (1984) Tumor heterogeneity and histopathology in epithelial ovarian cancer. Obstet Gynecol 63:330-334
34. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE (1994) Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 35:1771-1776
35. Keyes JW Jr (1995) SUV: Standard uptake or silly useless value? J Nucl Med 36:1836-1839
36. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H (2004) PET: A revolution in medical imaging. Radiol Clin North Am 42:983-1001
37. Rosenbaum SJ, Lind T, Antoch G, Bockisch A (2005) False-positive FDG PET uptake-the role of FDG/CT. Eur Radiol 16(5):1054-1065